MetaCap

ImmunityBio (IBRX) vs Kodiak Sciences (KOD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kodiak Sciences (KOD) has outperformed ImmunityBio (IBRX) over the past year, gaining 367.8% versus a gain of 189.4%. Over five years, KOD leads with a +3.0% price change compared with -7.4% for IBRX. ImmunityBio is the larger company by market cap ($6.40 billion vs $6.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBRX+189.42%KOD+367.84%
+478%+225%-28%
Nov 21, 20251 yearNov 20, 2026
IBRX-6.38%KOD-1.51%
+72%-18%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBRX versus KOD key metrics
MetricIBRXKOD
Share price$6.02$97.17
Market cap$6.40B$6.35B
1-day change-8.37%-0.75%
YTD return+204.04%+247.53%
1-year return+189.42%+367.84%
5-year return-7.38%+3.04%
EPS (TTM)$-1.06$-4.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$113.29M—
Revenue growth (YoY)+668.31%—
Net income (latest FY)$-351.40M$-229.97M
Gross margin99.34%—
Operating margin-226.00%—
Net margin-310.18%—
52-week high$12.43$112.79
52-week low$1.95$20.38
Distance from 52-week high-51.57%-13.85%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+136.71%+33.27%
Average volume12.97M1.77M
Shares outstanding1.06B65.40M
Employees684144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KOD has outperformed IBRX by 178.4 percentage points over the past year.

About ImmunityBio

IBRX stock →

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees

About Kodiak Sciences

KOD stock →

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

IBRX vs KOD FAQ

Which is bigger, ImmunityBio or Kodiak Sciences?

ImmunityBio (IBRX) is larger, with a market capitalization of $6.40B compared with $6.35B for Kodiak Sciences (KOD).

Which stock has performed better over the past year, IBRX or KOD?

KOD returned +367.84% over the past 12 months, compared with +189.42% for IBRX (price return, excluding dividends). Past performance does not predict future results.

Are ImmunityBio and Kodiak Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons